Quietly, CV Sciences Is Succeeding in a Competitive CBD Market

For years, marijuana stocks could do no wrong. All cannabis companies simply had to do was promise investors pie-in-the-sky growth over the long run, and their share prices shot into the heavens.

But following the legalization of recreational marijuana in Canada, this parade of promises is no longer sufficient to satiate investors. Nowadays, operating results actually matter, and most pot stocks have failed to generate sales growth and/or bottom-line improvements that validate their lofty valuations.

And it's not just Canada where these operating results matter. Marijuana stocks in the U.S. have been hit just the same if they've struggled to deliver on sales and profitability expectations. What's more, since the U.S. federal government has maintained a Schedule I classification on cannabis, pot stocks are forced to deal with the ramifications of operating in a federally illegal environment.

Continue reading

Source Fool.com